WASHINGTON — A key Senate Republican renewed his commitment to ramping up oversight of a controversial drug discount program in a hearing Tuesday.

Sen. Lamar Alexander of Tennessee, who chairs the Senate health committee, called for stricter reporting requirements and a closer examination of participants in the so-called 340B program, under which drug makers must give eligible hospitals discounts on their medicines. The hearing was his panel’s third examination of the program.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy